Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor
US12162859B2 · kind B2 · utility
0Cited by
28References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2021 |
| Grant date | Dec 10, 2024 |
| Priority date | — |
| Expiry date | Sep 13, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to polymorphic forms of (S)-3-(5-(4-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1- oxoisoindolin-2-yl)piperidine-2,6-dione, methods of making these polymorphic forms, and compositions comprising these polymorphic forms. These polymorphic forms are useful in the treatment of various diseases, including, for example, breast cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.